Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 3, 2012, Pages 203-207

  Mina, Ashraf ^a   Favaloro, Emmanuel J ^a   Koutts, Jerry ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

activated partial thromboplastin time; clotting factors; coagulation factors; phospholipids; procoagulant status; thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COLLAGEN BINDING PROTEIN; FIBRINOGEN; PHOSPHOLIPID; THROMBIN; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; THROMBIN TIME; THROMBOSIS; VELOCITY;

AREA UNDER CURVE; CASE-CONTROL STUDIES; COLLAGEN; FACTOR IX; FACTOR V; FACTOR VIII; FACTOR XI; FACTOR XII; FEMALE; FIBRINOGEN; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; PHOSPHOLIPIDS; PROTEIN BINDING; SPECTROMETRY, FLUORESCENCE; THROMBIN; THROMBOPLASTIN; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84859428596     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32834fa7d6     Document Type: Article

References (18)

1. Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008; 34:604-611.
2. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7:1737-1740.
3. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 2010; 21:459-463.
4. Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C. Pathophysiol Haemost Thromb 2002; 32:137-142. (Pubitemid 37490505)
5. Coppola A, Tufano A, Cerbone AM, Di Minno G. Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism. Semin Thromb Hemost 2009; 35:683-694.
6. Sugita C,Yamashita A, Moriguchi-Goto S, Furukoji E, Takahashi M,Harada A, et al. Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions. Thromb Res 2009; 124:601-607.
7. Ten Boekel E, Bock M, Vrielink GJ, Liem R, Hendriks H, de Kieviet W. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents. Thromb Res 2007; 121:361-367.
8. Mina A, Favaloro EJ, Mohammed S, Koutts J. A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul Fibrinolysis 2010; 21:152-157.
9. Zwaal RF, Comfurius P, Bevers EM. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180:1-8.
10. Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009; 35:60-75.
11. Favaloro EJ. Rethinking the diagnosis of von Willebrand disease. Thromb Res 2011; 127 (Suppl 2):S17-21.
12. Franchini M, Mannucci PM. Von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost 2008; 34:663-669.
13. Korte W, Clarke S, Lefkowitz JB. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 2000; 113:123-127. (Pubitemid 30217347)
14. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104:1009-1021.
15. Exner T, Joseph J, Low J, Connor D, Ma D. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid. Blood Coagul Fibrinolysis 2003; 14:773-779.
16. Reiner JS, Coyne KS, Lundergan CF, Ross AM. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 1994; 32: 49-52. (Pubitemid 24125424)
17. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004; 104:3631-3634. (Pubitemid 39564438)
18. Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol 2006; 134: 227-232. (Pubitemid 43893916)